COVID-19 vaccines can prevent corona related hospitalizations, deaths: CDC

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2021-04-30T20:45:00+05:30 | Updated On 1 May 2021 12:12 PM IST

USA: Recipients of the SARS-CoV-2 vaccine are at a lower risk of COVID-19-associated hospitalization, post-COVID complications, and death, according to a recent MMWR study.

The study found that Pfizer-BioNTech or Moderna COVID-19 vaccines were 94% effective against COVID-19 hospitalization among fully vaccinated adults and 64% effective among partially vaccinated adults aged ≥65 years.

Prior to this study, clinical trials have suggested high efficacy of the COVID-19 vaccine but there is a need for the evaluation of vaccine effectiveness against several outcomes in real-world settings and in high-risk populations, including older adults.

The study included 417 patients (187 case-patients and 230 controls) median age was 73 years for case-patients and controls, 48% were female. The patients were hospitalized with COVID-19–like illness in 14 states between January and March 2021. Some 45% tested positive for SARS-CoV-2 during their hospital stay (cases); the remainder tested negative (controls).

48% had one or more earlier hospitalizations in the last year, and 4% lived in a long-term care facility before admission. Among the 187 case-patients, 10% had received at least 1 dose of Pfizer-BioNTech or Moderna vaccine ≥14 days before illness onset (including 10% who were partially vaccinated and 0.5% who was fully vaccinated) compared with 27% of 230 test-negative controls (including 19% and 8% who were partially and fully vaccinated, respectively).

Key findings of the study include:

Prevalence of receipt of Pfizer-BioNTech and Moderna vaccines was similar (53% and 47%, respectively, among those vaccinated with ≥1 doses).
Adjusted VE for full vaccination using Pfizer-BioNTech or Moderna vaccine was 94%, and adjusted VE for partial vaccination was 64%.
There was no significant effect for receiving the first dose of a 2-dose COVID-19 vaccine series within 14 days before illness onset (adjusted VE = 3%).

"The findings suggest that SARS-CoV-2 vaccines can reduce the risk for COVID-19–associated hospitalization and, as a consequence of preventing severe COVID-19, vaccination might have an impact on post-COVID conditions (e.g., "long COVID") and deaths," concluded the authors.

Reference:

"Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021," published in MMWR.

DOI: https://www.cdc.gov/mmwr/volumes/70/wr/mm7018e1.htm#

SARS COV 2 vaccineCOVID 19MMWRCDC

Source : CDC' Morbidity and Mortality Weekly Report

Medha Baranwal

MSc. Biotechnology

Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751